SOLIACS: Solian Solution in the Acute Setting
|ClinicalTrials.gov Identifier: NCT00245674|
Recruitment Status : Completed
First Posted : October 28, 2005
Last Update Posted : April 10, 2008
During this study the efficacy and safety profile will be evaluated of the use of amisulpride in the form of a solution in schizophrenic patients with an acute episode.
The main purpose of the study is to observe the anti-psychotic effect of amisulpride as a solution during the first days of an acute episode of schizophrenia.
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Drug: amisulpride||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||300 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Solian Solution to Treat Schizophrenic Patients During an Acute Episode|
|Study Start Date :||June 2005|
- *analyze the antipsychotic efficacy of amisulpride solution in the first days of an acute schizophrenic episode.
- *analyse the safety profile of amisulpride solution in treatment of schizophrenics with an an acute episode.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00245674
|Study Director:||Dr. Christian Fassotte, M.D.||Sanofi|